{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["EGFR-TKI", "EGFR-TKI resistance", "G2/M cell cycle arrest", "aurora kinase A", "combination therapy", "non-small cell lung cancer", "quinazolin-4(3H)-one derivative"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35745617", "DateRevised": {"Year": "2022", "Month": "07", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "06", "Day": "02"}], "Language": ["eng"], "ELocationID": ["698", "10.3390/ph15060698"], "Journal": {"ISSN": "1424-8247", "JournalIssue": {"Volume": "15", "Issue": "6", "PubDate": {"Year": "2022", "Month": "Jun", "Day": "02"}}, "Title": "Pharmaceuticals (Basel, Switzerland)", "ISOAbbreviation": "Pharmaceuticals (Basel)"}, "ArticleTitle": "Antiproliferative Activity of a New Quinazolin-4(3<i>H</i>)-One Derivative via Targeting Aurora Kinase A in Non-Small Cell Lung Cancer.", "Abstract": {"AbstractText": ["Non-small cell lung cancer (NSCLC) is the most common lung cancer subtype. Although chemotherapy and targeted therapy are used for the treatment of patients with NSCLC, the survival rate remains very low. Recent findings suggested that aurora kinase A (AKA), a cell cycle regulator, is a potential target for NSCLC therapy. Previously, we reported that a chemical entity of quinazolin-4(3<i>H</i>)-one represents a new template for AKA inhibitors, with antiproliferative activity against cancer cells. A quinazolin-4(3<i>H</i>)-one derivative was further designed and synthesized in order to improve the pharmacokinetic properties and antiproliferation activity against NSCLC cell lines. The derivative, BIQO-19 (Ethyl 6-(4-oxo-3-(pyrimidin-2-ylmethyl)-3,4-dihydroquinazolin-6-yl)imidazo [1,2-a]pyridine-2-carboxylate), exhibited improved solubility and antiproliferative activity in NSCLC cells, including epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)-resistant NSCLC cells. BIQO-19 effectively inhibited the growth of the EGFR-TKI-resistant H1975 NSCLC cells, with the suppression of activated AKA (p-AKA) expression in these cells. The inhibition of AKA by BIQO-19 significantly induced G<sub>2</sub>/M phase arrest and subsequently evoked apoptosis in H1975 cells. In addition, the combination of gefitinib and BIQO-19 exhibited synergistic antiproliferative activity in NSCLC cells. These findings suggest the potential of BIQO-19 as a novel therapeutic agent for restoring the sensitivity of gefitinib in EGFR-TKI-resistant NSCLC cells."]}, "AuthorList": [{"Identifier": ["0000-0002-5969-1315"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Korea."}], "LastName": "Lee", "ForeName": "Ji Yun", "Initials": "JY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province, Chinese Academy of Sciences, Guiyang 550014, China."}], "LastName": "Yang", "ForeName": "Huarong", "Initials": "H"}, {"Identifier": ["0000-0003-1425-213X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Korea."}], "LastName": "Kim", "ForeName": "Donghwa", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Korea."}], "LastName": "Kyaw", "ForeName": "Kay Zin", "Initials": "KZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Korea."}], "LastName": "Hu", "ForeName": "Ruoci", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The Key Laboratory of Chemistry for Natural Products of Guizhou Province, Chinese Academy of Sciences, Guiyang 550014, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory for Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang 550014, China."}], "LastName": "Fan", "ForeName": "Yanhua", "Initials": "Y"}, {"Identifier": ["0000-0002-4306-7024"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Natural Products Research Institute, College of Pharmacy, Seoul National University, Seoul 08826, Korea."}], "LastName": "Lee", "ForeName": "Sang Kook", "Initials": "SK"}], "GrantList": [{"GrantID": "2019R1A2C2086476", "Agency": "National Research Foundation of Korea", "Country": ""}, {"GrantID": "21907020", "Agency": "National Natural Science Foundation of China", "Country": ""}, {"GrantID": "QKH-zk [2022]030", "Agency": "Natural Science Foundation of Guizhou Provincial Science and Technology Projects", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Pharmaceuticals (Basel)", "NlmUniqueID": "101238453", "ISSNLinking": "1424-8247"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. Cancer Statistics, 2021. CA Cancer J. Clin. 2021;71:7\u201333. doi: 10.3322/caac.21654.", "ArticleIdList": ["10.3322/caac.21654", "33433946"]}, {"Citation": "Herbst R.S., Heymach J.V., Lippman S.M. Lung Cancer. N. Engl. J. Med. 2008;359:1367\u20131380. doi: 10.1056/NEJMra0802714.", "ArticleIdList": ["10.1056/NEJMra0802714", "18815398"]}, {"Citation": "Warth A., Penzel R., Lindenmaier H., Brandt R., Stenzinger A., Herpel E., Goeppert B., Thomas M., Herth F., Dienemann H., et al. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: Patient outcome, interplay with morphology and immunophenotype. Eur. Respir. J. 2014;43:872\u2013883. doi: 10.1183/09031936.00018013.", "ArticleIdList": ["10.1183/09031936.00018013", "23988776"]}, {"Citation": "Prabhakar C.N. Epidermal growth factor receptor in non-small cell lung cancer. Transl. Lung Cancer Res. 2015;4:110\u2013118. doi: 10.3978/j.issn.2218-6751.2015.01.01.", "ArticleIdList": ["10.3978/j.issn.2218-6751.2015.01.01", "PMC4384217", "25870793"]}, {"Citation": "Liam C.-K., Pang Y.-K., Poh M.-E. EGFR Mutations in Asian Patients with Advanced Lung Adenocarcinoma. J. Thorac. Oncol. 2014;9:e70\u2013e71. doi: 10.1097/JTO.0000000000000251.", "ArticleIdList": ["10.1097/JTO.0000000000000251", "25122441"]}, {"Citation": "Kris M.G., Natale R.B., Herbst R.S., Lynch J.T., Jr., Prager D., Belani C.P., Schiller J.H., Kelly K., Spiridonidis H., Sandler A., et al. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non\u2013Small Cell Lung Cancer: A randomized trial. JAMA. 2003;290:2149\u20132158. doi: 10.1001/jama.290.16.2149.", "ArticleIdList": ["10.1001/jama.290.16.2149", "14570950"]}, {"Citation": "Costa D.B., Nguyen K.-S.H., Cho B.C., Sequist L.V., Jackman D.M., Riely G.J., Yeap B.Y., Halmos B., Kim J.H., J\u00e4nne P.A., et al. Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib. Clin. Cancer Res. 2008;14:7060\u20137067. doi: 10.1158/1078-0432.CCR-08-1455.", "ArticleIdList": ["10.1158/1078-0432.CCR-08-1455", "PMC2596582", "18981003"]}, {"Citation": "Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., Kris M.G., Miller V.A., Ladanyi M., Riely G.J. Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers. Clin. Cancer Res. 2013;19:2240\u20132247. doi: 10.1158/1078-0432.CCR-12-2246.", "ArticleIdList": ["10.1158/1078-0432.CCR-12-2246", "PMC3630270", "23470965"]}, {"Citation": "Mok T.S., Wu Y.-L., Ahn M.-J., Garassino M.C., Kim H.R., Ramalingam S.S., Shepherd F.A., He Y., Akamatsu H., Theelen W.S., et al. Osimertinib or Platinum\u2013Pemetrexed in EGFR T790M\u2013Positive Lung Cancer. N. Engl. J. Med. 2017;376:629\u2013640. doi: 10.1056/NEJMoa1612674.", "ArticleIdList": ["10.1056/NEJMoa1612674", "PMC6762027", "27959700"]}, {"Citation": "Yang Y., Zhang X., Wang R., Qin J., Wang J., Li Z., Song X. Osimertinib Resistance with a Novel EGFR L858R/A859S/Y891D Triple Mutation in a Patient with Non-Small Cell Lung Cancer: A Case Report. Front. Oncol. 2020;10:542277. doi: 10.3389/fonc.2020.542277.", "ArticleIdList": ["10.3389/fonc.2020.542277", "PMC7727459", "33324543"]}, {"Citation": "Chen J., Lu H., Zhou W., Yin H., Zhu L., Liu C., Zhang P., Hu H., Yang Y., Han H. AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827. Oncol. Rep. 2015;33:1860\u20131866. doi: 10.3892/or.2015.3764.", "ArticleIdList": ["10.3892/or.2015.3764", "PMC4440218", "25634113"]}, {"Citation": "Low J.-L., Lau D.P., Zhang X., Kwang X.-L., Rohatgi N., Chan J.V., Chong F.-T., Wong S.Q.R., Leong H.-S., Thangavelu M.T., et al. A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC) EBioMedicine. 2021;64:103220. doi: 10.1016/j.ebiom.2021.103220.", "ArticleIdList": ["10.1016/j.ebiom.2021.103220", "PMC7851772", "33529999"]}, {"Citation": "Carmena M., Earnshaw W.C. The cellular geography of Aurora kinases. Nat. Rev. Mol. Cell Biol. 2003;4:842\u2013854. doi: 10.1038/nrm1245.", "ArticleIdList": ["10.1038/nrm1245", "14625535"]}, {"Citation": "Willems E., Dedobbeleer M., Digregorio M., Lombard A., Lumapat P.N., Rogister B. The functional diversity of Aurora kinases: A comprehensive review. Cell Div. 2018;13:7. doi: 10.1186/s13008-018-0040-6.", "ArticleIdList": ["10.1186/s13008-018-0040-6", "PMC6146527", "30250494"]}, {"Citation": "Goldenson B., Crispino J.D. The aurora kinases in cell cycle and leukemia. Oncogene. 2015;34:537\u2013545. doi: 10.1038/onc.2014.14.", "ArticleIdList": ["10.1038/onc.2014.14", "PMC4167158", "24632603"]}, {"Citation": "Vader G., Lens S.M. The Aurora kinase family in cell division and cancer. Biochim. Biophys. Acta. 2008;1786:60\u201372. doi: 10.1016/j.bbcan.2008.07.003.", "ArticleIdList": ["10.1016/j.bbcan.2008.07.003", "18662747"]}, {"Citation": "Bischoff J.R., Anderson L., Zhu Y., Mossie K., Ng L., Souza B., Schryver B., Flanagan P., Clairvoyant F., Ginther C., et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. 1998;17:3052\u20133065. doi: 10.1093/emboj/17.11.3052.", "ArticleIdList": ["10.1093/emboj/17.11.3052", "PMC1170645", "9606188"]}, {"Citation": "Zhang Z., Singh M., Davidson S., Rosen D.G., Yang G., Liu J. Activation of BTAK expression in primary ovarian surface epithelial cells of prophylactic ovaries. Mod. Pathol. 2007;20:1078\u20131084. doi: 10.1038/modpathol.3800945.", "ArticleIdList": ["10.1038/modpathol.3800945", "17673924"]}, {"Citation": "G\u00f6rg\u00fcn G., Calabrese E., Hideshima T., Ecsedy J., Perrone G., Mani M., Ikeda H., Bianchi G., Hu Y., Cirstea D., et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010;115:5202\u20135213. doi: 10.1182/blood-2009-12-259523.", "ArticleIdList": ["10.1182/blood-2009-12-259523", "PMC2892955", "20382844"]}, {"Citation": "Kaestner P., Stolz A., Bastians H. Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol. Cancer Ther. 2009;8:2046\u20132056. doi: 10.1158/1535-7163.MCT-09-0323.", "ArticleIdList": ["10.1158/1535-7163.MCT-09-0323", "19584233"]}, {"Citation": "Du J., Yan L., Torres R., Gong X., Bian H., Marug\u00e1n C., Boehnke K., Baquero C., Hui Y.-H., Chapman S.C., et al. Aurora A\u2013Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy. Mol. Cancer Ther. 2019;18:2207\u20132219. doi: 10.1158/1535-7163.MCT-18-0529.", "ArticleIdList": ["10.1158/1535-7163.MCT-18-0529", "31530649"]}, {"Citation": "Ndolo K.M., Park K.R., Lee H.J., Yoon K.B., Kim Y.-C., Han S.-Y. Characterization of the Indirubin Derivative LDD970 as a Small Molecule Aurora Kinase A Inhibitor in Human Colorectal Cancer Cells. Immune Netw. 2017;17:110\u2013115. doi: 10.4110/in.2017.17.2.110.", "ArticleIdList": ["10.4110/in.2017.17.2.110", "PMC5407982", "28458622"]}, {"Citation": "Wang L.-X., Wang J.-D., Chen J.-J., Long B., Liu L.-L., Tu X.-X., Luo Y., Hu Y., Lin D.-J., Lu G., et al. Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation. Sci. Rep. 2016;6:35533. doi: 10.1038/srep35533.", "ArticleIdList": ["10.1038/srep35533", "PMC5099696", "27824120"]}, {"Citation": "Min Y.H., Kim W., Kim J.-E. The Aurora kinase A inhibitor TC-A2317 disrupts mitotic progression and inhibits cancer cell proliferation. Oncotarget. 2016;7:84718\u201384735. doi: 10.18632/oncotarget.12448.", "ArticleIdList": ["10.18632/oncotarget.12448", "PMC5356694", "27713168"]}, {"Citation": "Dos Santos E.O., Carneiro-Lobo T.C., Aoki M.N., Levantini E., Bass\u00e8res D.S. Aurora kinase targeting in lung cancer reduces KRAS-induced transformation. Mol. Cancer. 2016;15:12. doi: 10.1186/s12943-016-0494-6.", "ArticleIdList": ["10.1186/s12943-016-0494-6", "PMC4739397", "26842935"]}, {"Citation": "Shah K.N., Bhatt R., Rotow J., Rohrberg J., Olivas V., Wang V.E., Hemmati G., Martins M.M., Maynard A., Kuhn J., et al. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat. Med. 2019;25:111\u2013118. doi: 10.1038/s41591-018-0264-7.", "ArticleIdList": ["10.1038/s41591-018-0264-7", "PMC6324945", "30478424"]}, {"Citation": "Blakely C.M., Gubens M.A., Allen G.M., Shah S., Jereza M., Bacaltos B., Bandyopadhyay S. Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer. J. Clin. Oncol. 2021;39:9074. doi: 10.1200/JCO.2021.39.15_suppl.9074.", "ArticleIdList": ["10.1200/JCO.2021.39.15_suppl.9074"]}, {"Citation": "Du R., Huang C., Liu K., Li X., Dong Z. Targeting AURKA in Cancer: Molecular mechanisms and opportunities for Cancer therapy. Mol. Cancer. 2021;20:15. doi: 10.1186/s12943-020-01305-3.", "ArticleIdList": ["10.1186/s12943-020-01305-3", "PMC7809767", "33451333"]}, {"Citation": "O\u2019Connor O.A., \u00d6zcan M., Jacobsen E.D., Roncero J.M., Trotman J., Demeter J., Masszi T., Pereira J., Ramchandren R., Beaven A., et al. Randomized Phase III Study of Alisertib or Investigator\u2019s Choice (Selected Single Agent) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. J. Clin. Oncol. 2019;37:613\u2013623. doi: 10.1200/JCO.18.00899.", "ArticleIdList": ["10.1200/JCO.18.00899", "PMC6494247", "30707661"]}, {"Citation": "Yan V.C., Butterfield H.E., Poral A.H., Yan M.J., Yang K.L., Pham C.-D., Muller F.L. Why Great Mitotic Inhibitors Make Poor Cancer Drugs. Trends Cancer. 2020;6:924\u2013941. doi: 10.1016/j.trecan.2020.05.010.", "ArticleIdList": ["10.1016/j.trecan.2020.05.010", "PMC7606322", "32536592"]}, {"Citation": "Al-Salahi R., Abuelizz H.A., Ghabbour H.A., El-Dib R., Marzouk M. Molecular docking study and antiviral evaluation of 2-thioxo-benzo[g]quinazolin-4(3H)-one derivatives. Chem. Central J. 2016;10:21. doi: 10.1186/s13065-016-0168-x.", "ArticleIdList": ["10.1186/s13065-016-0168-x", "PMC4837545", "27099618"]}, {"Citation": "Nanda A.K., Ganguli S., Chakraborty R. Antibacterial Activity of Some 3-(Arylideneamino)-2-phenylquinazoline-4(3H)-ones: Synthesis and Preliminary QSAR Studies. Molecules. 2007;12:2413\u20132426. doi: 10.3390/12102413.", "ArticleIdList": ["10.3390/12102413", "PMC6149171", "17978766"]}, {"Citation": "Zayed M.F., Hassan M. Synthesis and biological evaluation studies of novel quinazolinone derivatives as antibacterial and anti-inflammatory agents. Saudi Pharm. J. 2014;22:157\u2013162. doi: 10.1016/j.jsps.2013.03.004.", "ArticleIdList": ["10.1016/j.jsps.2013.03.004", "PMC3950501", "24648828"]}, {"Citation": "Mahdy H.A., Ibrahim M.K., Metwaly A., Belal A., Mehany A.B., El-Gamal K.M., El-Sharkawy A., Elhendawy M.A., Radwan M.M., ElSohly M.A., et al. Design, synthesis, molecular modeling, in vivo studies and anticancer evaluation of quinazolin-4(3H)-one derivatives as potential VEGFR-2 inhibitors and apoptosis inducers. Bioorg. Chem. 2020;94:103422. doi: 10.1016/j.bioorg.2019.103422.", "ArticleIdList": ["10.1016/j.bioorg.2019.103422", "31812261"]}, {"Citation": "Fan Y.-H., Li W., Liu D.-D., Bai M.-X., Song H.-R., Xu Y., Lee S., Zhou Z.-P., Wang J., Ding H.-W. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2- a ]pyridine and quinazolin-4(3H)-one derivatives as PI3K\u03b1 inhibitors. Eur. J. Med. Chem. 2017;139:95\u2013106. doi: 10.1016/j.ejmech.2017.07.074.", "ArticleIdList": ["10.1016/j.ejmech.2017.07.074", "28800461"]}, {"Citation": "Wang P.-F., Jensen A.A., Bunch L. From Methaqualone and Beyond: Structure\u2013Activity Relationship of 6-, 7-, and 8-Substituted 2,3-Diphenyl-quinazolin-4(3H)-ones and in Silico Prediction of Putative Binding Modes of Quinazolin-4(3H)-ones as Positive Allosteric Modulators of GABAA Receptors. ACS Chem. Neurosci. 2020;11:4362\u20134375. doi: 10.1021/acschemneuro.0c00600.", "ArticleIdList": ["10.1021/acschemneuro.0c00600", "33170625"]}, {"Citation": "Kumar D., Mariappan G., Husain A., Monga J., Kumar S. Design, synthesis and cytotoxic evaluation of novel imidazolone fused quinazolinone derivatives. Arab. J. Chem. 2017;10:344\u2013350. doi: 10.1016/j.arabjc.2014.07.001.", "ArticleIdList": ["10.1016/j.arabjc.2014.07.001"]}, {"Citation": "Safavi M., Ashtari A., Khalili F., Mirfazli S.S., Saeedi M., Ardestani S.K., Ranjbar P.R., Tehrani M.B., Larijani B., Mahdavi M. Novel quinazolin-4(3H)-one linked to 1,2,3-triazoles: Synthesis and anticancer activity. Chem. Biol. Drug Des. 2018;92:1373\u20131381. doi: 10.1111/cbdd.13203.", "ArticleIdList": ["10.1111/cbdd.13203", "29637699"]}, {"Citation": "Hieu D.T., Anh D.T., Hai P.T., Thuan N.T., Huong L.T.T., Park E.J., Ji A.Y., Kang J.S., Dung P.T.P., Han S.B., et al. Quinazolin-4(3H)-one-Based Hydroxamic Acids: Design, Synthesis and Evaluation of Histone Deacetylase Inhibitory Effects and Cytotoxicity. Chem. Biodivers. 2019;16:e1800502. doi: 10.1002/cbdv.201800502.", "ArticleIdList": ["10.1002/cbdv.201800502", "30653817"]}, {"Citation": "Thakur A., Tawa G.J., Henderson M.J., Danchik C., Liu S., Shah P., Wang A.Q., Dunn G., Kabir M., Padilha E.C., et al. Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. J. Med. Chem. 2020;63:4256\u20134292. doi: 10.1021/acs.jmedchem.0c00193.", "ArticleIdList": ["10.1021/acs.jmedchem.0c00193", "PMC7238858", "32212730"]}, {"Citation": "Ke Y.-Y., Shiao H.-Y., Hsu Y.C., Chu C.-Y., Wang W.-C., Lee Y.-C., Lin W.-H., Chen C.-H., Hsu J.T.A., Chang C.-W., et al. 3D-QSAR-Assisted Drug Design: Identification of a Potent Quinazoline-Based Aurora Kinase Inhibitor. ChemMedChem. 2013;8:136\u2013148. doi: 10.1002/cmdc.201200464.", "ArticleIdList": ["10.1002/cmdc.201200464", "23172777"]}, {"Citation": "Fan C., Zhong T., Yang H., Yang Y., Wang D., Yang X., Xu Y., Fan Y. Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition. Eur. J. Med. Chem. 2020;190:112108. doi: 10.1016/j.ejmech.2020.112108.", "ArticleIdList": ["10.1016/j.ejmech.2020.112108", "32058239"]}, {"Citation": "Liu K., Zheng M., Lu R., Du J., Zhao Q., Li Z., Li Y., Zhang S. The role of CDC25C in cell cycle regulation and clinical cancer therapy: A systematic review. Cancer Cell Int. 2020;20:213. doi: 10.1186/s12935-020-01304-w.", "ArticleIdList": ["10.1186/s12935-020-01304-w", "PMC7268735", "32518522"]}, {"Citation": "Dutto I., Tillhon M., Cazzalini O., Stivala L.A., Prosperi E. Biology of the cell cycle inhibitor p21CDKN1A: Molecular mechanisms and relevance in chemical toxicology. Arch. Toxicol. 2015;89:155\u2013178. doi: 10.1007/s00204-014-1430-4.", "ArticleIdList": ["10.1007/s00204-014-1430-4", "25514883"]}, {"Citation": "Kim D., Bach D.-H., Fan Y.-H., Luu T.-T., Hong J.-Y., Park H.J., Lee S.K. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells. Cell Death Dis. 2019;10:361. doi: 10.1038/s41419-019-1601-6.", "ArticleIdList": ["10.1038/s41419-019-1601-6", "PMC6494839", "31043587"]}, {"Citation": "Chen M.-C., Chen C.-H., Wang J.-C., Tsai A.-C., Liou J.-P., Pan S.-L., Teng C.-M. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death Dis. 2013;4:e810. doi: 10.1038/cddis.2013.330.", "ArticleIdList": ["10.1038/cddis.2013.330", "PMC3789188", "24052078"]}, {"Citation": "Pai-Scherf L., Blumenthal G.M., Li H., Subramaniam S., Mishra-Kalyani P.S., He K., Zhao H., Yu J., Paciga M., Goldberg K.B., et al. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist. 2017;22:1392\u20131399. doi: 10.1634/theoncologist.2017-0078.", "ArticleIdList": ["10.1634/theoncologist.2017-0078", "PMC5679831", "28835513"]}, {"Citation": "To K.K.W., Fong W., Cho W.C.S. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. Front. Oncol. 2021;11:635007. doi: 10.3389/fonc.2021.635007.", "ArticleIdList": ["10.3389/fonc.2021.635007", "PMC8185359", "34113560"]}, {"Citation": "Eymin B., Gazzeri S. Role of cell cycle regulators in lung carcinogenesis. Cell Adhes. Migr. 2010;4:114\u2013123. doi: 10.4161/cam.4.1.10977.", "ArticleIdList": ["10.4161/cam.4.1.10977", "PMC2852568", "20139697"]}, {"Citation": "Kamran M., Long Z.-J., Xu D., Lv S.-S., Liu B., Wang C.-L., Xu J., Lam E., Liu Q. Aurora kinase A regulates Survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis. Oncogenesis. 2017;6:e298. doi: 10.1038/oncsis.2016.80.", "ArticleIdList": ["10.1038/oncsis.2016.80", "PMC5337621", "28218735"]}, {"Citation": "Nikhil K., Raza A., Haymour H.S., Flueckiger B.V., Chu J., Shah K. Aurora Kinase A-YBX1 Synergy Fuels Aggressive Oncogenic Phenotypes and Chemoresistance in Castration-Resistant Prostate Cancer. Cancers. 2020;12:660. doi: 10.3390/cancers12030660.", "ArticleIdList": ["10.3390/cancers12030660", "PMC7140108", "32178290"]}, {"Citation": "Zou Z., Yuan Z., Zhang Q., Long Z., Chen J., Tang Z., Zhu Y., Chen S., Xu J., Yan M., et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy. 2012;8:1798\u20131810. doi: 10.4161/auto.22110.", "ArticleIdList": ["10.4161/auto.22110", "PMC3541289", "23026799"]}, {"Citation": "Fan Y., Lu H., Ma H., Feng F., Hu X., Zhang Q., Wang J., Xu Y., Zhao Q. Bioactive compounds of Eriocaulon sieboldianum blocking proliferation and inducing apoptosis of HepG2 cells might be involved in Aurora kinase inhibition. Food Funct. 2015;6:3746\u20133759. doi: 10.1039/C5FO00371G.", "ArticleIdList": ["10.1039/C5FO00371G", "26369427"]}, {"Citation": "Wishart D.S., Guo A., Oler E., Wang F., Anjum A., Peters H., Dizon R., Sayeeda Z., Tian S., Lee B.L., et al. HMDB 5.0: The Human Metabolome Database for 2022. Nucleic Acids Res. 2022;50:D622\u2013D631. doi: 10.1093/nar/gkab1062.", "ArticleIdList": ["10.1093/nar/gkab1062", "PMC8728138", "34986597"]}, {"Citation": "Beltran H., Oromendia C., Danila D.C., Montgomery B., Hoimes C., Szmulewitz R.Z., Vaishampayan U., Armstrong A.J., Stein M., Pinski J., et al. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin. Cancer Res. 2019;25:43\u201351. doi: 10.1158/1078-0432.CCR-18-1912.", "ArticleIdList": ["10.1158/1078-0432.CCR-18-1912", "PMC6320304", "30232224"]}, {"Citation": "Chu Q.S.-C., Bouganim N., Fortier C., Zaknoen S., Stille J.R., Kremer J.D., Yuen E., Hui Y.-H., de la Pe\u00f1a A., Lithio A., et al. Aurora kinase A inhibitor, LY3295668 erbumine: A phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors. Investig. New Drugs. 2021;39:1001\u20131010. doi: 10.1007/s10637-020-01049-3.", "ArticleIdList": ["10.1007/s10637-020-01049-3", "33479856"]}, {"Citation": "Mou P.K., Yang E.J., Shi C., Ren G., Tao S., Shim J.S. Aurora kinase A, a synthetic lethal target for precision cancer medicine. Exp. Mol. Med. 2021;53:835\u2013847. doi: 10.1038/s12276-021-00635-6.", "ArticleIdList": ["10.1038/s12276-021-00635-6", "PMC8178373", "34050264"]}, {"Citation": "Jung C., Hong J.-Y., Bae S.Y., Kang S.S., Park H.J., Lee S.K. Antitumor Activity of Americanin A Isolated from the Seeds of Phytolacca americana by Regulating the ATM/ATR Signaling Pathway and the Skp2\u2013p27 Axis in Human Colon Cancer Cells. J. Nat. Prod. 2015;78:2983\u20132993. doi: 10.1021/acs.jnatprod.5b00743.", "ArticleIdList": ["10.1021/acs.jnatprod.5b00743", "26595875"]}, {"Citation": "Gy\u0151rffy B., Surowiak P., Budczies J., L\u00e1nczky A. Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer. PLoS ONE. 2013;8:e82241. doi: 10.1371/journal.pone.0082241.", "ArticleIdList": ["10.1371/journal.pone.0082241", "PMC3867325", "24367507"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "4", "Day": "29"}, {"Year": "2022", "Month": "5", "Day": "24"}, {"Year": "2022", "Month": "5", "Day": "31"}, {"Year": "2022", "Month": "6", "Day": "24", "Hour": "1", "Minute": "37"}, {"Year": "2022", "Month": "6", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "6", "Day": "25", "Hour": "6", "Minute": "1"}, {"Year": "2022", "Month": "6", "Day": "2"}], "PublicationStatus": "epublish", "ArticleIdList": ["35745617", "PMC9228987", "10.3390/ph15060698", "ph15060698"]}}], "PubmedBookArticle": []}